Elixiron closes $27M series A for Alzheimer's and vitiligo clinical trials

Elixiron Immunotherapeutics has closed a $27 million series A to test its lead asset in Alzheimer's disease patients and advance a pipeline of immuno-oncology assets.

The biotech has been testing its lead asset, EI-1071, in a phase 1 trial in healthy volunteers to test its safety and tolerability. With the new financing, Elixiron aims to test the oral inhibitor in patients with Alzheimer's. The biotech also picked up a $1 million grant from the Alzheimer's Association almost a year ago to the day for the study of the memory-robbing disease.